Nucleobindin 2 in human breast carcinoma as a potent prognostic factor
Article first published online: 17 NOV 2011
© 2011 Japanese Cancer Association
Volume 103, Issue 1, pages 136–143, January 2012
Total views since publication: 0
How to Cite
Suzuki, S., Takagi, K., Miki, Y., Onodera, Y., Akahira, J.-i., Ebata, A., Ishida, T., Watanabe, M., Sasano, H. and Suzuki, T. (2012), Nucleobindin 2 in human breast carcinoma as a potent prognostic factor. Cancer Science, 103: 136–143. doi: 10.1111/j.1349-7006.2011.02119.x
- Issue published online: 6 JAN 2012
- Article first published online: 17 NOV 2011
- Accepted manuscript online: 11 OCT 2011 01:15PM EST
- (Received June 20, 2011/Revised September 15, 2011/Accepted September 27, 2011/Accepted manuscript online October 11, 2011/Article first published online November 17, 2011)
Table S1. Genes predominantly expressed in the non-recurrence group, classified as group B.
Table S2. Association between nucleobindin 2 (NUCB2) status and clinicopathological parameters according to estrogen receptor status in 161 breast carcinomas.
|CAS_2119_sm_TableS1-S2.doc||107K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.